Tectonic Therapeutic Inc/$TECX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tectonic Therapeutic Inc
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
Ticker
$TECX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
51
Website
TECX Metrics
BasicAdvanced
$417M
-
-$4.72
-
-
Price and volume
Market cap
$417M
52-week high
$27.04
52-week low
$13.70
Average daily volume
231K
Financial strength
Current ratio
22.92
Quick ratio
22.668
Long term debt to equity
0.094
Total debt to equity
0.874
Interest coverage (TTM)
-659.84%
Profitability
EBITDA (TTM)
-61.717
Management effectiveness
Return on assets (TTM)
-22.89%
Return on equity (TTM)
-41.59%
Valuation
Price to book
1.38
Price to tangible book (TTM)
1.38
Price to free cash flow (TTM)
-4.4
Free cash flow yield (TTM)
-22.73%
Free cash flow per share (TTM)
-507.28%
Growth
Earnings per share change (TTM)
-88.53%
Bulls say / Bears say
Tectonic Therapeutic announced positive interim data from its Phase 1b trial for TX45, showing improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in HFpEF. (nasdaq.com)
The company secured approximately $185 million through a private investment in public equity financing, enhancing its financial position to advance clinical programs. (nasdaq.com)
Analysts have given Tectonic Therapeutic a consensus 'Buy' rating, with an average 12-month price target of $72.25, indicating strong growth potential. (slatersentinel.com)
Vanguard Group Inc. reduced its holdings in Tectonic Therapeutic by 18.5% during the fourth quarter, potentially signaling decreased confidence from a major institutional investor. (marketbeat.com)
The company's net loss for Q3 2024 was $17.7 million, reflecting ongoing financial challenges despite a strong cash position. (nasdaq.com)
While positive, the interim data from the TX45 Phase 1b trial is still early-stage, and the success of future phases remains uncertain, posing a risk to the company's pipeline. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tectonic Therapeutic Inc stock?
Tectonic Therapeutic Inc (TECX) has a market cap of $417M as of July 28, 2025.
What is the P/E ratio for Tectonic Therapeutic Inc stock?
The price to earnings (P/E) ratio for Tectonic Therapeutic Inc (TECX) stock is 0 as of July 28, 2025.
Does Tectonic Therapeutic Inc stock pay dividends?
No, Tectonic Therapeutic Inc (TECX) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next Tectonic Therapeutic Inc dividend payment date?
Tectonic Therapeutic Inc (TECX) stock does not pay dividends to its shareholders.
What is the beta indicator for Tectonic Therapeutic Inc?
Tectonic Therapeutic Inc (TECX) does not currently have a Beta indicator.